ImmVirX develops receptor-targeted oncolytic viruses for cancer treatment, focusing on prevalent cancer types with limited treatment options.

ImmVirX

ImmVirX is an Australian company founded in 2019 with a mission to improve outcomes for patients with cancer types in which immunotherapy treatments have limited effect.  The company is developing a bio-selected RNA virus to induce tumour inflammation and achieve immune cell infiltration via the RIG-I pathway. The targets for this approach are Ovarian, Head & Neck and those indications which present with liver metastases such as Colorectal, Hepatocellular carcinoma and Pancreatic cancer. The approach includes combination therapy with Immune Checkpoint Inhibitors and CAR-T agents using bio-selected RNA virus.
The company founders, Malcolm McColl and Prof. Darren Shafren, were Managing Director and CSO of Viralytics, an ASX listed oncolytic virus company acquired in June 2018 by Merck and Co. Inc. for A$502 million.  The ImmVirX team includes key management and researchers from Viralytics and is based at the former Viralytics laboratory facilities in Newcastle Australia.

Great update on our clinical program by CEO Malcolm McColl and CSO Darren Shafren on Oncology for the Inquisitive Mind Podcast. Thank you to the team for inviting us on to share our recent progress.

ImmVirX has presented an update showing promising signals in its Phase 1a/b study targeting solid cancers at the MOGA Annual Meeting.   IVX037 has been well tolerated, with signs of monotherapy activity, in particular in late-stage colorectal cancer patients: https://buff.ly/3Mac4Mw

ImmVirX is pleased to have CSO Darren Shafren and Medical Director Oksana Zdanska attending the 2024 Medical Oncology Group of Australia (MOGA) Annual Scientific Meeting this week. 

An update from the phase 1a monotherapy trial of our lead candidate, IVX037 will be provided in a Poster presentation from Dr Jia (Jenny) Liu on 15th August. A Phase 1b featuring IVX037 in combination with Innovent's checkpoint inhibitor TYVYT will commence in the coming months.

ImmVirX is pleased to advise that Co-Founder and CEO Dr Malcolm McColl's presentation at The Bell Potter Securities Healthcare Conference 2023 is now available.

Click here to view the presentation: https://lnkd.in/gpQxeAH7

We are pleased to announce the appointment of Dr Oksana Zdanska as Medical Director, commencing today: https://buff.ly/49y35hH

Dr. Zdanska is a highly regarded clinical leader with extensive experience in clinical trials, including drug development of novel treatments. She has know-how and familiarity with cutting edge technologies including the use of oncolytic immunotherapies in clinical settings.

We are pleased to share a replay of CEO & Acting Chairman Dr Malcolm McColl's presentation at the NWR Virtual Healthcare Conference.

Shareholders and other interested parties can view the presentation at: https://buff.ly/3PLzXfE

IMMV

COM:IMMVIRX

ImmVirX